Resolution Therapeutics' macrophage therapy raises $85 million

Oct 3, 2024 · Today, Resolution Therapeutics, a clinical-stage biotech company, secured $85 million (£63.5 million) in series B financing to advance its lead product candidate, RTX001, into clinical trials. The financing led by Syncona will enable the company to push forward its …

CouponFollow Extension

$85
OFF

Resolution Therapeutics' Macrophage Therapy Raises $85 Million

6 days from now

labiotech.eu

$83
OFF

Resolution Scores $83m To Develop Macrophage Cell Therapies

6 days from now

Oct 3, 2024 · Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based company plans to use the money to …

pharmaceutical-technology.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

yahoo.com

£64
OFF

Resolution’s £64M Series B To Advance Macrophage Cell Therapy

6 days from now

Oct 3, 2024 · A preview of the next edition of BioWorld, Oct. 3, 2024. Resolution Therapeutics Ltd. is preparing for a phase I/II trial of its autologous engineered macrophage cell therapy, RTX …

bioworld.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Mar 10, 2024 · Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the …

synconaltd.com

$85
OFF

Resolution Raises $85M To Test Macrophage Therapies In End-stage …

6 days from now

Oct 3, 2024 · By the end of the year, a British biotech plans to start testing a new kind of cell therapy based on macrophages, a roaming immune … Sign up to read this article for free.

endpts.com

$65
OFF

Resolution Therapeutics Secures $65 Million In Funding To …

6 days from now

Resolution Therapeutics is thrilled to announce the successful completion of a $65 million funding round, marking a significant milestone in our mission to revolutionize treatment options for …

leadsontrees.com

FAQs about Resolution Therapeutics' macrophage therapy raises $85 million Coupon?

Who founded resolution Therapeutics?

In 2020, Professor Forbes co-founded Resolution Therapeutics, a biotech company focused on engineering macrophage cell therapies to deliver a more effective and durable treatment for patients with end-stage liver disease. ...

What is resolution Therapeutics?

Resolution Therapeutics presents novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy ...

When did resolution Therapeutics get MHRA approval?

Resolution Therapeutics approval from the MHRA follows the presentation of key proof of concept data by the University of Edinburgh at the European Association for the Study of the Liver (EASL) Congress 2024 which took place from 5 to 8 June in Milan, Italy. Resolution Therapeutics spun out from the University of Edinburgh in 2020. ...

How much did resolution raise in Series B financing?

Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. The round adds to an earlier £26.6 million (US$ 35 million) Series A financing in 2020. ...

Can macrophage cells regenerate tissue after injury?

Forbes and Campbell demonstrated that macrophage cells, a type of white blood cell that plays multiple roles including surrounding and killing pathogenic microbes, can help the body to regenerate tissue after injury. Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. ...

Is autologous macrophage cell therapy effective?

This study provides a clinical proof-of-concept that autologous macrophage cell therapy is well-tolerated and efficacious, supporting Resolution’s mission to develop improved macrophage cell therapy products designed for commercialisation. ...